These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
- TG Therapeutics (TGTX), 255% surge in interest
- Protalix BioTherapeutics (PLX), 234% surge in interest
- Arrowhead Pharma (ARWR), 173% surge in interest
- Moderna (MRNA), 113% surge in interest
- Evofem Biosciences (EVFM), 87% surge in interest
Pipeline and key clinical candidates for these companies:
TG Therapeutics is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the FDA for Briumvi, for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Protalix is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. "Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix’s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner," the company has stated.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA, or mRNA, to "an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale," the company states. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has "allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing." Most recently, Moderna’s capabilities have come together to allow the authorized use and approval of vaccines against the COVID pandemic. The company is pursuing the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.
Evofem Biosciences is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The company’s first FDA-approved product, Phexxi, is a hormone-free, on-demand prescription contraceptive vaginal gel.
Recent news on these stocks:
April 14
H.C. Wainwright raised the firm’s price target on TG Therapeutics to $28 from $24 and kept a Buy rating on the shares. The analyst lowered the firm’s Q2 sales estimate for Briumvi to $10.4M from $10.6M, but increased its Briumvi sales estimates for the latter half of the year, which brings its 2023 Briumvi sales estimate to $47.1M from $46.1M. A potential European approval is expected to be about six to nine months behind the U.S. approval, the analyst told investors in a research note.
April 12
SVB Securities upgraded Arrowhead to Outperform from Market Perform with a price target of $35, up from $21. Shares have underperformed year-to-date relative to larger cap oligonucleotide therapy peers, yielding an appetizing risk/reward profile for shares heading into upcoming data catalysts for the pulmonary portfolio, the analyst told investors in a research note.
After Moderna hosted its annual Vaccines Day, BofA said the firm "wouldn’t be surprised if shares continue to trade under pressure" given Moderna’s seasonal flu program, mRNA-1010, received notice that the iDSMB interim review recommended continuation of efficacy follow-up. Following the delay, the firm suspects investor interest may turn to the updated mRNA-1010 flu vaccine, which is set to initiate a confirmatory phase 3 trial this month. BofA, which contends that it was "left with more questions than answers" from the event, has a Neutral rating and $200 price target on Moderna shares.
Hear more from InvestingChannel by signing up for The Spill.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVFM:
